De novo design and discovery of potent, nonpeptidal HIV-1 protease inhibitors
- DuPont Merck Pharmaceutical Co., Wilmington, DE (United States)
Intense worldwide research in HIV-1 protease inhibition has resulted in many inhibitors with nanomolar Ki. However, they are mostly pseudopeptides (containing amide bonds) and substrate-like. In this work the authors report that using 3-D database searching, computer modeling and x-ray structures of the HIV-1 protease/inhibitor complex, a completely novel class of potent nonpeptides has been designed and synthesized. The Ki is in the subnanomolar range and the IC90 for the cell assays in the submicromolar range. Confirmation of the mode of binding was achieved by a high resolution x-ray structure of a HIV-1 protease/inhibitor complex. Molecular recognition studies between HIV-1 protease and these inhibitors will also be discussed.
- OSTI ID:
- 141134
- Report Number(s):
- CONF-930304-; TRN: 93:003688-0809
- Resource Relation:
- Conference: 205. American Chemical Society national meeting, Denver, CO (United States), 28 Mar - 2 Apr 1993; Other Information: PBD: 1993; Related Information: Is Part Of 205th ACS national meeting; PB: 1951 p.
- Country of Publication:
- United States
- Language:
- English
Similar Records
A Novel Bis-Tetrahydrofuranylurethane-Containing Nonpeptidic Protease Inhibitor (PI), GRL-98065, Is Potent Against Mulutiple-PI-Resistant Human Immunodeficiency Virus in Vitro
Design, Synthesis, and X-ray Structure of Substituted Bis-tetrahydrofuran (Bis-THF)-Derived Potent HIV-1 Protease Inhibitors